American biotech companies are racing to do business with China, and for good reasons: It offers a new market for their drugs. It’s a new source of investment for nascent companies. And it’s a new place to conduct clinical trials.

But to operate in China, you need to build relationships — an exercise that can be far different than what companies experience in the United States. In interviews, experts who have actually worked in the country told STAT that they could not overestimate the importance of face-to-face meetings, how they use emails, as well as an awareness that dealmaking in China can be happen at a different pace — some things are often slower, some faster — than in the United States.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy